Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 3
2007 1
2008 2
2010 1
2015 1
2018 1
2019 3
2020 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissières P, Royal S, Faust SN; HARMONIE Study Group. Drysdale SB, et al. N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189. N Engl J Med. 2023. PMID: 38157500 Clinical Trial.
Randomized Trial of Platelet-Transfusion Thresholds in Neonates.
Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D'Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T; PlaNeT2 MATISSE Collaborators. Curley A, et al. N Engl J Med. 2019 Jan 17;380(3):242-251. doi: 10.1056/NEJMoa1807320. Epub 2018 Nov 2. N Engl J Med. 2019. PMID: 30387697 Clinical Trial.
Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen.
Gupta S, Subhedar NV, Bell JL, Field D, Bowler U, Hutchison E, Johnson S, Kelsall W, Pepperell J, Roberts T, Sinha S, Stanbury K, Wyllie J, Hardy P, Juszczak E; Baby-OSCAR Collaborative Group. Gupta S, et al. N Engl J Med. 2024 Jan 25;390(4):314-325. doi: 10.1056/NEJMoa2305582. N Engl J Med. 2024. PMID: 38265644 Free PMC article. Clinical Trial.
Examination of the role of sphingosine kinase 2 in a murine model of systemic lupus erythematosus.
Mohammed S, Vineetha NS, James S, Aparna JS, Lankadasari MB, Allegood JC, Li QZ, Spiegel S, Harikumar KB. Mohammed S, et al. FASEB J. 2019 Jun;33(6):7061-7071. doi: 10.1096/fj.201802535R. Epub 2019 Mar 6. FASEB J. 2019. PMID: 30840833 Free PMC article.
Yet, because its deletion had no effect on the clinical lupus parameters in this preclinical model, inhibitors of SphK2 might not be useful for treatment of this devastating disease.-Mohammed, S., Vineetha, N. S., James, S., Aparna, J. S., Lankadasari, …
Yet, because its deletion had no effect on the clinical lupus parameters in this preclinical model, inhibitors of SphK2 might not be useful …
Two-year outcomes following a randomised platelet transfusion trial in preterm infants.
Moore CM, D'Amore A, Fustolo-Gunnink S, Hudson C, Newton A, Santamaria BL, Deary A, Hodge R, Hopkins V, Mora A, Llewelyn C, Venkatesh V, Khan R, Willoughby K, Onland W, Fijnvandraat K, New HV, Clarke P, Lopriore E, Watts T, Stanworth S, Curley A; PlaNeT2 MATISSE. Moore CM, et al. Arch Dis Child Fetal Neonatal Ed. 2023 Sep;108(5):452-457. doi: 10.1136/archdischild-2022-324915. Epub 2023 Feb 21. Arch Dis Child Fetal Neonatal Ed. 2023. PMID: 36810309 Free PMC article.
PATIENTS: 660 infants born at less than 34 weeks' gestation with platelet counts less than 5010(9)/L. INTERVENTIONS: Infants were randomised to undergo a platelet transfusion at platelet count thresholds of 5010(9)/L (higher threshold group) or 2510(9)/L (low …
PATIENTS: 660 infants born at less than 34 weeks' gestation with platelet counts less than 5010(9)/L. INTERVENTIONS: Infants were ran …
Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
Harikumar KG, Miller LJ. Harikumar KG, et al. J Biol Chem. 2005 May 13;280(19):18631-5. doi: 10.1074/jbc.M410834200. Epub 2005 Mar 9. J Biol Chem. 2005. PMID: 15757907 Free article.
We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and within the helical bundle of the cholecystokinin receptor to the amino terminus of a full agonist CCK analogue (Harikumar, K. G., Pinon, …
We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and with …
Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor.
Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, Miller LJ. Harikumar KG, et al. J Biol Chem. 2005 Jan 21;280(3):2176-85. doi: 10.1074/jbc.M410385200. Epub 2004 Nov 10. J Biol Chem. 2005. PMID: 15537636 Free article.
Receptor conformation was probed with a fluorescent full agonist ligand, Alexa 488-conjugated Gly-[Nle(28,31)]CCK-(26-33), shown previously to decrease in anisotropy and lifetime when occupying a receptor in the active conformation (Harikumar, K. G., Pinon, D. L., W …
Receptor conformation was probed with a fluorescent full agonist ligand, Alexa 488-conjugated Gly-[Nle(28,31)]CCK-(26-33), shown previously …
Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ. Harikumar KG, et al. J Biol Chem. 2005 Jan 14;280(2):1044-50. doi: 10.1074/jbc.M409480200. Epub 2004 Nov 1. J Biol Chem. 2005. PMID: 15520004 Free article.
We utilized this methodology to determine the environment of Alexa within a cholecystokinin (CCK)-like probe (Alexa488-Gly-[(Nle(28,31))CCK-26-33]; CCK-8 probe) bound to the type A CCK receptor (Harikumar, K. G., Pinon, D. L., Wessels, W. S., Prendergast, F. …
We utilized this methodology to determine the environment of Alexa within a cholecystokinin (CCK)-like probe (Alexa488-Gly-[(Nle(28,31))CCK- …
Resveratrol: a multitargeted agent for age-associated chronic diseases.
Harikumar KB, Aggarwal BB. Harikumar KB, et al. Cell Cycle. 2008 Apr 15;7(8):1020-35. doi: 10.4161/cc.7.8.5740. Epub 2008 Feb 15. Cell Cycle. 2008. PMID: 18414053 Review.
Resveratrol has also been shown to activate various transcription factor (e.g; NFkappaB, STAT3, HIF-1alpha, beta-catenin and PPAR-gamma), suppress the expression of antiapoptotic gene products (e.g; Bcl-2, Bcl-X(L), XIAP and survivin), inhibit protein kinases (e.g; src, PI …
Resveratrol has also been shown to activate various transcription factor (e.g; NFkappaB, STAT3, HIF-1alpha, beta-catenin and PPAR-gamma), su …
Rational development of a high-affinity secretin receptor antagonist.
Dong M, Harikumar KG, Raval SR, Milburn JE, Clark C, Alcala-Torano R, Mobarec JC, Reynolds CA, Ghirlanda G, Christopoulos A, Wootten D, Sexton PM, Miller LJ. Dong M, et al. Biochem Pharmacol. 2020 Jul;177:113929. doi: 10.1016/j.bcp.2020.113929. Epub 2020 Mar 23. Biochem Pharmacol. 2020. PMID: 32217097 Free PMC article.
A key new step in this effort was the replacement of peptide residue Leu(22) with L-cyclohexylalanine (Cha) to enhance potential hydrophobic interactions with receptor residues Leu(31), Val(34), and Phe(92) that were predicted from molecular modeling. ...
A key new step in this effort was the replacement of peptide residue Leu(22) with L-cyclohexylalanine (Cha) to enhance potential hydr …
17 results